Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:19838039rdf:typepubmed:Citationlld:pubmed
pubmed-article:19838039lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C0442034lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C0024623lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C0008838lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C0144576lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C0123931lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C0879262lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C1533148lld:lifeskim
pubmed-article:19838039lifeskim:mentionsumls-concept:C0205221lld:lifeskim
pubmed-article:19838039pubmed:issue10lld:pubmed
pubmed-article:19838039pubmed:dateCreated2009-10-19lld:pubmed
pubmed-article:19838039pubmed:abstractTextThe patient was a 63-year-old male with multiple peritoneal disseminations of advanced gastric cancer. He underwent chemotherapy with a combination of S-1 120 mg/day (3 weeks administration and 2 weeks rest) and cisplatin (CDDP) 60 mg/m(2) (day 8). After 3 courses of this regimen, CT revealed no evidence of ascites. He then underwent laparatomy. Peritoneal dissemination appeared, and the findings were sT3, N0, H0, P1, CY1, M1(PLE), sStage IV. A bypass operation was performed. As second-line chemotherapy, he received combination chemotherapy with S-1 and paclitaxel (PTX) 60 mg/m(2) (div), 20 mg/m(2) ( ip) (day 1, 8). However, he complained of ascites after 16 courses. We tried weekly administration of PTX and tri-weekly administration of irinotecan (50 mg/m(2)) with S-1. This treatment was successfully continued for 20 courses. The adverse effect was anemia (grade 2). He died two years eight months after surgery. The chemotherapy with S-1/CDDP, S-1/PTX, and S-1/PTX/irinotecan was thought to be effective for advanced gastric cancer with peritoneal dissemination.lld:pubmed
pubmed-article:19838039pubmed:languagejpnlld:pubmed
pubmed-article:19838039pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:citationSubsetIMlld:pubmed
pubmed-article:19838039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:19838039pubmed:statusMEDLINElld:pubmed
pubmed-article:19838039pubmed:monthOctlld:pubmed
pubmed-article:19838039pubmed:issn0385-0684lld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:KobayashiKeit...lld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:IkedaHideakiHlld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:KatohHiroshiHlld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:KoderaMasahit...lld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:YamashitaYuta...lld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:YamamuraMasao...lld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:OishiMasahiro...lld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:SeshimoKenKlld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:YokomichiNaos...lld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:TakitaKeikoKlld:pubmed
pubmed-article:19838039pubmed:authorpubmed-author:KanagawaTaiic...lld:pubmed
pubmed-article:19838039pubmed:issnTypePrintlld:pubmed
pubmed-article:19838039pubmed:volume36lld:pubmed
pubmed-article:19838039pubmed:ownerNLMlld:pubmed
pubmed-article:19838039pubmed:authorsCompleteYlld:pubmed
pubmed-article:19838039pubmed:pagination1741-4lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:meshHeadingpubmed-meshheading:19838039...lld:pubmed
pubmed-article:19838039pubmed:year2009lld:pubmed
pubmed-article:19838039pubmed:articleTitle[A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].lld:pubmed
pubmed-article:19838039pubmed:affiliationDept. of Surgery, Tottori Municipal Hospital.lld:pubmed
pubmed-article:19838039pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:19838039pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:19838039pubmed:publicationTypeCase Reportslld:pubmed